AVAX Technologies Inc (CE) (AVXT) Cotización

Maybe the $50's today.

Looks thin to win. Not seeing much resistance on the chart now. Looks like it cleared the hurdle.

AVXT: As of May 25, 2021, TD Ameritrade will restrict orders in Caveat Emptor designated OTC securities to liquidating trades only.

A Caveat Emptor security is a designation the OTC Markets Group places on a security after a determination was made surrounding the company that there may be potential risk to investors which include a questionable stock promotion, known investigation of fraudulent activity committed by the company or insiders, regulatory suspensions, or disruptive corporate actions, among other reasons.

The current list of Caveat Emptor restricted securities is below as of April 12, 2021 and is subject to change at any time.
Please visit www.otcmarkets.com for additional details and real time Caveat Emptor desiginations.

https://www.tdameritrade.com/retail-en_us/resources/pdf/cesecuritylist.pdf

Solid Trading Today. Is there any update on the clinical trial results?

Bought Back In! Word Is Getting Out Regarding MVAX Clinical Trials!

Holy Crap I sold in the 002's!!!!! Damn it

Estimated Study Completion Date: January 2021
https://www.clinicaltrials.gov/ct2/show/NCT00477906?term=avax&draw=2&rank=1

It's A$k Smacking Time!

Will Today's Buy @ .0024 Be Tomorrows .24?

Some-Bod (s) R REALLY Trying to Keep A LID ON AVXT... Hmmm

The paper's getting thin @ .003; is a bust out on the horizon?

THERAPEUTIC CANCER VACCINES: MARKET NEW LEVEL TRENDS, PERSPECTIVE OF TOP VENDORS LIKE ANTIGENICS, VAXIMM, ASTERIAS BIOTHERAPEUTICS, BAYER, GLAXOSMITHKLINE, AVAX TECHNOLOGIES, MODERNA
Post author
By Sameer Joshi
Post date
July 2, 2020
The research report on Therapeutic Cancer Vaccines Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Therapeutic Cancer Vaccines Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period.

Therapeutic Cancer Vaccines Market report provides in-depth statistics and analysis available on the market status of the Therapeutic Cancer Vaccineskey players and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Therapeutic Cancer Vaccines market. It contains the analysis of drivers, challenges, and restraints impacting the industry.

Some of the keyplayers of Therapeutic Cancer Vaccines Market:

Antigenics
VAXIMM
Asterias Biotherapeutics
Bayer
GlaxoSmithKline
Avax Technologies
Moderna
Mayo Clinic
Northwest Biotherapeutics
Merck



https://jewishlifenews.com/uncategorized/therapeutic-cancer-vaccines-market-new-level-trends-perspective-of-top-vendors-like-antigenics-vaximm-asterias-biotherapeutics-bayer-glaxosmithkline-avax-technologies-moderna/

Let's Clear Those 003's!!!

Nice Volume So Far Today 306k. Large Bids Stacking Up 4M @ 0016-0017. This Is Getting Good!

4M share bid @ .0017 is sure sign of AVXT waking up.

5.Key Vendors
– Who are the major players in the Therapeutic Vaccines business?

– What growth strategies are major giants adopting?

Northeast Biotherapeutics
Agenus
Vaccinogen Inc
CIMAB S.A
Dendreon
Corixa
AVAX Technologies

– Also, what share do they control?

– What developments have they undertaken?


https://3wnews.org/reports/1045237/global-therapeutic-vaccines-market-2020-with-potential-impact-of-covid19-northeast-biotherapeutics-agenus-vaccinogen-inc/

Bring on the .003's!!! Woot Woot!

WTH? News???

Not me Brotha I'm GEEKED UP 4 What's Com'n! Bring on the A$k Slaps.

Thought AVAX was dead and buried???

Emerging Cancer Vaccines Market to Develop New Growth Story: Emerging Segments is the Key
BY MICHAEL YARBROUGH ON NOVEMBER 22, 2019

HTF MI recently introduced Global Emerging Cancer Vaccines Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2022. At present, the market is developing its presence and some of the key players from the complete study are Antigenics, Avax Technologies, GlaxoSmithKline, Merck, Moderna & Northwest Biotherapeutics etc. The market Study is segmented by key regions which is accelerating the marketization.

https://www.marketjournal.co.uk/emerging-cancer-vaccines-market-to-develop-new-growth-story-emerging-segments-is-the-key/51434/

Should be avax

Abscess merged with someone and went private. This is just mm play

Nice vol here today

Definite upwards trend here; higher ask and thinning!

L2 keeps shifting look like she wants to go.

this looks very thin

Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026 - AVXT

https://www.oaoa.com/news/business/article_c461ff1c-bbc3-5d98-992d-a4a0cdff9eed.html

ReNewed interest in this Ticker; Something is brewing... I like it adding.

The Power of Immunotherapy!

Well, that was Firebird, because they pretty much financed Avax over the years and were not stupid to lose all that money for nothing. Even the principals of BioVaxys are formerly involved with Avax no mather if they say otherwise. The problem was not that the science was not there and actually very effective in saving lives, but being a good scientist does not make you a good businessman. To have something that works and not be able to bring it to market in 20 years says everything. Now they transferred all that knowledge and clinical trials to the new company and you can bet that soon enough it will go public to raise new capital. Of course, common shareholders of Avax lost everything.
But hey, look at the bright side Powerbattles, if you lost money in Avax you can use it to offset the huge profits you're going to make with UCPA.

So sad that they are gone as a shell right now.

Startingboy is probably right in his posts below ...


Post 1567:
... the news say is a global licence so maybe AVXT still got some value or they use to r/m BIOVAXYS LLC into it in the future.


Post 1569:
... it looks like firebird fund take all the goodies from avxt to BioVaxys, so avxt is done or a shell.

I was wonder how BioVaxys manage to transfer all avxt asset?

You can contact Mr. Kovan with your words at the following email address, he will answer you within 24 hours:

kkovan@biovaxys.com

The shareholders will thank you if you want to share news on this board!

Well, you could contact Mr. Kovan again and tell him to tell Dr.Berd to expect a lawsuit from Avax common shareholders.

thanks for sharing man. well it looks like firebird fund take all the goodies from avxt to BioVaxys, so avxt is done or a shell .

I don't know if you owner AVAX shares and if you are waiting-for a rebirth of AVAX, however I received Mr. Kovan's reply:

… BioVaxys is an entirely new entity and is separate from what was Avax. I do not know the specifics with Avax as I was never involved on their management team nor had any position with them. But from what I do know, Avax is no longer in business. BioVaxys just recently acquired some of the remaining unexpired Avax patents (which had been in default), and has also filed its own new IP on novel compositions/methods for achieving better efficacy across a broad range of tumor types. Avax was a very exciting company and made major progress with its melanoma and ovarian cancer programs, and it is unfortunate that they are no longer operating as I believe they could have saved lives with their vaccines. Although we intend to leverage some of that pedigree, we are doing it as a separate company with a somewhat different approach that we believe will be superior. …


* What do you think about, shareholders own only paper for the trash?

not i don't to your first question,i just discover that yesterday, and my best advise to you is not worth it to sell at this low price , the news say
is a global licence so maybe AVXT still got some value or they use to r/m BIOVAXYS LLC into it in the future .

Thank you very much for links ... did you emailed Dr. Berd to find out if AVXT was abandoned along with the shareholders?

I think they took away the license with Vax technology and created a new biopharma called BioVaxys ...

Anyway, I can't understand how AVXT does to exist and survive on OTC market ...

I still own 100K AVXT shares that are worth a dinner at restaurant, I am undecided whether to sell now that AVXT is still listed on the OTC market ...

What do you advise me to do?
Happy New Year to You and Longer Shareholders!

https://biovaxys.com/

looks like dr berd & firebird fund move all the assets to a private company?
https://biovaxys.com/leadership-team

https://www.businesswire.com/news/home/20180709005142/en/Thomas-Jefferson-University-BioVaxys-LLC-Enter-Exclusive

Question: If AVXT'S Outstanding share count is 142.61M, then what's the float? Gotta be ridiculously low.

They are no longer at their location. Type in their address into google. It's an anti violence Philly Org. Type in the suite no as well.

I'm loving it !!!

Melanoma Global Market 2017: Key Players: AB Science, Amgen, Array BioPharma, AVAX Technologies and More

https://marketersmedia.com/melanoma-global-market-2017-key-players-ab-science-amgen-array-biopharma-avax-technologies-and-more/286000

For a dead ticker AVXT sure is showing positive signs of life....

Volume traded today is over 2M. HMMMMMM.........

Thank you 4 the cheap shares @ .001 today!

They don't have any web site. how can.we.believe it? may be out of cash